Transformation of the mitochondrial genome.
V Larosa, C Remacle - International Journal of …, 2013 - search.ebscohost.com
Although mitochondrial transformation is highly desirable in mammals and plants, it is only
possible in two unicellular organisms, the budding yeast Saccharomyces cerevisiae and the …
possible in two unicellular organisms, the budding yeast Saccharomyces cerevisiae and the …
Discovery of small molecule interactors of human ArfGAP1 and their potential use for the treatment of Parkinson's disease
K Strynatka - 2023 - dalspace.library.dal.ca
Parkinson's disease (PD), a movement disorder affecting primarily elderly patients, is the
second most common neurodegenerative disease. The majority of cases are idiopathic …
second most common neurodegenerative disease. The majority of cases are idiopathic …
[PDF][PDF] 肿瘤治疗中小分子激酶抑制剂的研究进展
徐祎春， 韩峻松， 李跃 - 生命科学, 2016 - lifescience.sinh.ac.cn
激酶在肿瘤细胞的生长, 增殖和凋亡过程中起着重要作用, 因此, 研发相关的激酶抑制剂调控相应
的信号转导通路已是现今抗肿瘤药物开发的趋势. 至今, 已有29 个肿瘤小分子激酶抑制剂经美国 …
的信号转导通路已是现今抗肿瘤药物开发的趋势. 至今, 已有29 个肿瘤小分子激酶抑制剂经美国 …
[PDF][PDF] 蛋白激酶与神经变性疾病
杨胜乾， 杜冠华 - 中国药理学与毒理学杂志, 2014 - cjpt.magtechjournal.com
神经变性疾病是由于神经元或者髓鞘的损伤, 丢失引起的神经系统疾病, 其病因复杂,
影响因素甚多, 发病机制尚不完全明确. 蛋白激酶在神经变性疾病的发生发展过程中发挥着重要 …
影响因素甚多, 发病机制尚不完全明确. 蛋白激酶在神经变性疾病的发生发展过程中发挥着重要 …